Floatz logo

Vts-K

Central Nervous System Depressants

Theresa Jacob, PhD, MPHPhase 4 / ApprovedActive
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Central Nervous System Depressants cohort.

Asset / SponsorPhaseRating
ly03010
Luye Pharma Group Ltd.
Phase 1CC
Paliperidone Palmitate 3-Month Formulation
Luye Pharma Group Ltd.
Phase 1CC
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Aretaieion University Hospital
N/AD
FENTANYL
Aretaieion University Hospital
N/AD
Bxcl501
Aretaieion University Hospital
N/AD
LIDOCAINE
Aretaieion University Hospital
N/AD

Same molecule, other indications

Vts-K is also rated in:

Peripheral Nervous System AgentsDormant
BB
Indicative ·
69 / 100
View asset →
Anti-Inflammatory AgentsDormant
BB
Indicative ·
69 / 100
View asset →
Physiological Effects of DrugsDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →